查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
全球再生医学市场：到 2028 年的预测——按产品、材料、应用、最终用户和地区分析
市场调查报告书
商品编码
1218897

全球再生医学市场：到 2028 年的预测——按产品、材料、应用、最终用户和地区分析

Regenerative Medicine Market Forecasts to 2028 - Global Analysis By Product, Material, Application, End User and Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 175+ Pages | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC，全球再生医学市场规模将在 2022 年达到 350.1 亿美元，到 2028 年达到 739.4 亿美元，预测期内復合年增长率为 13.27%。

再生医学修復因疾病、外伤或先天性缺陷而受损的组织和器官，这与目前侧重于治疗症状的临床策略不同。 再生医学包括组织工程、细胞疗法、医疗器械、人造器官等，是实现这些突破的方法。 再生医学是一个令人兴奋的领域，旨在修復受损的组织和器官并恢復其功能。 它还旨在寻找治疗永久性受损器官的方法。 这种方法旨在找到治愈以前无法治癒的疾病和伤害的方法。

根据再生医学联盟 (ARM) 2021 年报告，该市场的全球融资将从 2020 年的 199 亿美元增加到 2021 年的 227 亿美元，支持 2,406 种在研产品的增加。

市场动态

驱动程序

增加对研发活动的投资，从而推出创新产品

该行业不断增加的投资导致了严肃的研发业务，各种投资者支持专注于开发市场上的新型疗法和产品的初创企业。 它还为大规模合併、研究合作和伙伴关係铺平了道路，以从研发活动中获益。 除了商业公司，许多政府和政府资助的研究机构都在该行业致力于开发针对多种慢性疾病的有效治疗方法，包括癌症、帕金森病、糖尿病、肾臟疾病和心血管疾病。正在积极投资于

抑製剂

高昂的治疗费用和不完善的保险报销政策

这些产品的高昂治疗费用和不充分的报销规定是市场扩张的主要障碍。 由于没有大型保险公司的保险范围，患者别无选择，只能自费或通过众筹支付治疗费用，这会延误治疗并阻碍市场增长。 此外，对于患有各种遗传疾病的广大患者群体而言，批准的治疗方法数量有限，这些方法相当昂贵并且可能有其他副作用，这限制了它们的采用并促进了市场的增长。正在阻止

机会

主要公司的战略收购

全球再生医学市场的趋势是，主要竞争对手都在进行战略收购以扩大其研发能力。 这个市场上的产品是从活细胞、蛋白质、□、抗体、抗体-药物偶联物 (ADC)、基因和细胞成分开发的各种专有技术，用于为各种慢性疾病创造救命药物。 然而，将这些技术应用于临床时，愿望与现实之间可能存在不匹配。 一些领先的公司正专注于收购以提高其研发能力，以填补这一空白并推进针对不同临床应用的研究。

威胁

缺乏熟练的专业人员

随着再生医学的进步，必要的技能有望得到发展。 再生医学生物製造的快速扩张造成了该领域所需技能与市场容量之间的不匹配。 儘管对细胞和基因治疗 (CGT) 业务进行了大量投资，但由于缺乏合格人员，製造这些药物已被证明具有挑战性。 劳动力有限和对新药生产的了解不足导致 CGT 的商业化进程缓慢。

COVID-19 的影响

COVID-19 大流行为运营商提供了一个有利可图的机会，因为迫切需要发现针对 SARS-COV-2 的新药。 细胞和基因治疗製造业正在进行多个项目，包括 T 细胞治疗领域。 例如，新加坡杜克-新加坡国立大学医学院的新发传染病研究项目已经证明了这些免疫疗法在治疗感染 COVID-19 的患者中的有效性，这是基于先前的研究。 政府和公司为支持研发而采取的许多举措和持续资助也加速了该行业的发展。 同样，市场参与者为再生医学研发筹集资金的举措也在支持市场进步。

组织工程领域预计在预测期内将成为最大的领域

由于伤口护理中对支架、生物基质等产品的需求增加，组织工程领域预计将实现利润丰厚的增长。 组织工程领域的高份额主要是由于能够用完全活的结构替换受损结构的能力以及为以前无法治疗的医学问题找到治疗方法的希望。 此外，为创造有效疗法而进行的大量研发投资以及不断推出成功的新产品预计将推动对组织工程行业的需求。

预计肿瘤科在预测期内的复合年增长率最高

由于全球癌症发病率高以及对开发癌症治疗新技术的需求不断增长，预计肿瘤学在预测期内将以最快的复合年增长率增长。 癌症患病率不断上升等因素导致癌症患者群体的巨大需求未得到满足，许多新药（如 CAR-T 细胞疗法）应运而生以满足这一需求。 此外，通过研究资助和宣传活动增加政府支持正在推动该领域的发展。

市场份额最高的地区

由于美国有众多主要参与者，北美预计在预测期内将占据最大的市场份额。 该地区拥有参与创新疗法开发的先进技术和研究机构，临床试验的数量可能会有所贡献。 与政府机构和私营公司的许多举措一样，财务灵活性是美国最大的收入来源。

复合年增长率最高的地区

随着亚太地区新兴国家扩大基础设施和设施以促进干细胞研究，预计在预测期内復合年增长率最高。 在日本，厚生劳动省于2013年4月通过了《再生医学法》，为再生医学和细胞疗法的临床发展铺平了道路。 同样，中国政府已经批准了各种关于人类胚胎干细胞的研究项目，鼓励研究人员探索这些细胞的临床潜力。

主要发展

2021年1月，Integra Life Sciences Holdings Co., Ltd.完成对ACell, Inc.的收购。 收购 ACell 及其专有的 MatriStem UBM 技术将使 Integra 能够为患者提供更全面的综合伤口管理解决方案。

2021 年 1 月，Eli Lilly收购了 Prevail Therapeutics，旨在利用 Prevail 基于腺相关病毒 (AAV) 9 的基因疗法治疗神经退行性疾□□病患者，从而扩大与建立基因疗法的协议程序。 此次收购扩大了以新方法解决神经退行性疾□□病的致命遗传形式的努力。 此次收购增加了重要的技术和一支技术精湛的团队，以补充Eli Lilly现有的专业知识。

2020 年 11 月，Novartis与 Mesoblast 达成协议，开发、商业化和製造用于治疗急性呼吸窘迫综合征 (ARDS) 的 Remestemcel-L。 Remestemcel-L 可能是 ARDS 的第一个治疗方法，它使用基于细胞的平台技术，即间充质基质细胞 (MSCs) 来治疗这种致命疾病并改善预后。 在签订该许可协议后，Novartis计划在与 COVID-19无关的 ARDS 中启动 III 期试验。

2020 年 10 月，Bayer AG收购了 Asklepios Biopharmaceutical，以拓宽其在细胞和基因治疗领域的创新视野。 因此，Bayer AG的细胞和基因治疗平台有可能为需求未得到满足的多个疾病领域的患者带来治疗。

2018 年 10 月，Mesoblast Limited 扩大了与 JCR Pharmaceuticals Co., Ltd. 的合作伙伴关係。 在日本，一家日本公司开发了间充质干细胞 (MSC)，用于治疗新生儿缺氧缺血性脑病 (HIE)，这是一种大脑缺乏足够血液供应和氧气的疾病。与 JCR 扩大了合作关係。

本报告的内容

  • 区域和国家/地区细分市场份额评估
  • 针对新进入者的战略建议
  • 2020、2021、2022、2025 和 2028 年的综合市场数据
  • 涵盖市场趋势（市场驱动因素、驱动因素、机遇、威胁、挑战、投资机会、建议）
  • 根据市场预测在关键业务领域提出战略建议
  • 竞争格局映射主要共同趋势
  • 公司简介，包括详细的战略、财务状况和近期发展
  • 映射最新技术进步的供应链趋势

免费定制服务

订阅此报告的客户将免费获得以下自定义选项之一。

  • 公司简介
    • 其他市场参与者的综合概况（最多 3 家公司）
    • 主要参与者的 SWOT 分析（最多 3 家公司）
  • 区域细分
    • 根据客户要求对主要国家/地区的市场进行估算、预测和復合年增长率（注意：基于可行性检查。）
  • 竞争基准
    • 根据产品组合、地域分布和战略联盟对主要参与者进行基准测试

内容

第 1 章执行摘要

第二章前言

  • 概览
  • 利益相关者
  • 调查范围
  • 调查方法
    • 数据挖掘
    • 数据分析
    • 数据验证
    • 研究方法
  • 调查来源
    • 主要研究信息来源
    • 二手研究资源
    • 假设

第三章市场趋势分析

  • 司机
  • 约束因素
  • 机会
  • 威胁
  • 产品分析
  • 应用分析
  • 最终用户分析
  • 新兴市场
  • COVID-19 的影响

第4章波特五力分析

  • 供应商的议价能力
  • 买家的议价能力
  • 替代品的威胁
  • 新进入者的威胁
  • 竞争公司之间的敌对关係

第 5 章全球再生医学市场：按产品分类

  • 祖细胞和干细胞疗法
  • 基因治疗
  • 人体组织工程
  • 细胞疗法
  • 其他产品

第 6 章全球再生医学市场：按材料分类

  • 转基因材料
    • 转基因
    • 基因工程细胞
    • 基因激活矩阵
    • 神经干细胞
    • 三维聚合物技术
    • 成纤维细胞
  • 合成材料
    • 人工血管移植材料
    • 水凝胶材料
    • 脚手架
  • 生物材料
    • 异质材料
    • 胶原蛋白
  • 医药
    • 生物的

第 7 章全球再生医学市场：按应用

  • 肿瘤科
  • 伤口护理
  • 心血管
  • 肌肉骨骼
  • 眼科
  • 其他应用

第 8 章全球再生医学市场：按最终用户分类

  • 政府和学术研究机构
  • 医院和诊所
  • 商业行业

第 9 章全球再生医学市场：按地区

  • 北美
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 意大利
    • 法国
    • 西班牙
    • 其他欧洲
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳大利亚
    • 新西兰
    • 韩国
    • 其他亚太地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 其他南美洲
  • 中东和非洲
    • 沙特阿拉伯
    • 阿拉伯联合酋长国
    • 卡塔尔
    • 南非
    • 其他中东地区

第10章主要发展

  • 合同、伙伴关係、协作和合资企业
  • 收购与合併
  • 新产品发布
  • 业务扩展
  • 其他关键策略

第11章公司简介

  • Smith & Nephew plc
  • Shenzhen SibionoGeneTech Co., Ltd.
  • AstraZeneca
  • Aspect Biosystems
  • Integra LifeSciences Corporation
  • Novartis AG
  • Medtronic plc
  • Amgen, Inc.
  • MiMedx Group
  • Baxter
  • Eli Lilly & Co.
  • Mesoblast Ltd.
  • Bayer AG
  • Corestem, Inc.
  • Bluebird Bio, Inc.
  • Regrow Biosciences Pvt. Ltd.Eli Lilly
Product Code: SMRC22433

According to Stratistics MRC, the Global Regenerative Medicine Market is accounted for $35.01 billion in 2022 and is expected to reach $73.94 billion by 2028 growing at a CAGR of 13.27% during the forecast period. Regenerative medicine repairs tissue or organs that have been damaged by disease, trauma, or congenital abnormalities, as opposed to the present clinical strategy, which focuses mostly on treating symptoms. The methods used to attain these breakthroughs include tissue engineering, cellular therapy, medical devices, and artificial organs. Regenerative medicine is an exciting field that aims to repair and restore the structure and function of damaged tissues and organs. It also intends to discover cures for permanently injured organs. This approach aims to find a cure for previously incurable illnesses and injuries.

According to the Alliance for Regenerative Medicine (ARM) 2021 report, the global financing in this market was raised to USD 22.7 billion in 2021 from USD 19.9 billion in 2020 to support 2,406 products that are under investigation.

Market Dynamics:

Driver:

Increasing investments in R&D activities leading to innovative product launches

Increasing investments in this sector have resulted in full-fledged research and development operations, as various investors support start-up firms focusing on the development of novel cures and products in the market. This has also paved the path for large mergers, research collaborations, and partnerships to profit from R&D operations. Aside from commercial businesses, numerous government and government-funded research organisations are aggressively investing in this industry to develop viable treatment options for a variety of chronic conditions such as cancer, Parkinson's disease, diabetes, renal disorders, cardiovascular diseases, and others.

Restraint:

High treatment costs and inadequate reimbursement policies

The high costs of therapy with these products, as well as a lack of reimbursement rules, are major obstacles limiting market expansion. Due to the lack of coverage provided by the major insurance providers, patients' only options are to pay for treatment out of pocket or through crowd fundraising, which delays treatment and inhibits market growth. Moreover, there are limited approved therapies for a wide range of patient population suffering from various genetic disorders which are considerably expensive and may have other side effects which restrains its adoption, limiting the market growth.

Opportunity:

Strategic acquisitions by key market players

One of the most prevalent worldwide regenerative medicine market trends is the incorporation of strategic acquisitions by key competitors in order to expand their R&D capabilities. This market's goods include a variety of unique techniques developed from living cells and protein, enzymes, antibodies, antibody-drug conjugates (ADC), gene and cellular components that have resulted in life-saving medicines for a variety of chronic diseases. However, there may be a mismatch between aspirations and realities when it comes to putting these technologies into clinical practise. Some significant businesses are focusing on acquisitions to boost their R&D capabilities in order to bridge this gap and develop research in diverse clinical applications.

Threat:

Shortage of skilled professionals

The skills necessary are projected to evolve as regenerative medicine progresses. Regenerative medicine bio manufacturing is rapidly expanding, resulting in a mismatch between the skill sets required by labourers in the workplace and the market's incapacity to fill those positions. Despite significant investment in the cell and gene therapies (CGT) business, producing these medicines has proven difficult due to a dearth of competent individuals. A limited workforce and inadequate understanding involved with manufacturing novel and emerging medicines contribute to the slow commercialization of CGTs.

COVID-19 Impact

The COVID-19 pandemic presented profitable chances for operational players due to the urgent need for the discovery of novel medicines against SARS-COV-2. Several projects are being conducted in the cell and gene therapy manufacturing industry, including the T-cell therapy space. For example, the Duke-NUS medical school's emerging infectious diseases research programme in Singapore demonstrated the usefulness of these immunotherapies in treating patients with COVID-19 infection based on earlier research findings. The availability of many initiatives and ongoing funding by government and corporate entities to assist R&D also accelerates the industry's advancement. Similarly, initiatives adopted by market players to raise finance for the R&D of regenerative medicine support the market progression.

The tissue-engineering segment is expected to be the largest during the forecast period

The tissue-engineering segment is estimated to have a lucrative growth, due to increased demand for its products, such as scaffolds, bio matrixes, and others in wound care. The primary reason for the large share of the tissue-engineering segment is the ability to replace a damaged structure with a totally living structure, as well as the promise for finding remedies for previously untreatable medical problems. Furthermore, significant investment in research & development for generating effective treatments, as well as the continuous introduction of new and successful products, are projected to drive demand in the tissue engineering industry.

The oncology segment is expected to have the highest CAGR during the forecast period

The oncology segment is anticipated to witness the fastest CAGR growth during the forecast period, due to the high incidence of cancer globally and increasing demand for development of new technologies for the treatment of cancer. Factors such as the increased prevalence of cancer have resulted in huge unmet cancer patient population demands, and numerous novel medicines, such as CAR-T cell therapy, have been created to meet this demand. Furthermore, increased active government support through research grants and awareness campaigns is adding to the segment's growth.

Region with highest share:

North America is projected to hold the largest market share during the forecast period owing to the presence of a significant number of key players in the U.S. The presence of advanced technology and research institutes involved in the development of innovative treatments contribute to the high number of clinical trials in this region. The availability of finances, as well as many initiatives by government and private organisations, contributes to the largest revenue flow from the United States.

Region with highest CAGR:

Asia Pacific is projected to have the highest CAGR over the forecast period, owing to the expansion of infrastructure and facilities to accelerate stem cell research in the emerging economies of the region. In Japan, the Ministry of Health, Labor, and Welfare passed the Regenerative Medicine Law in April 2013, paving the way for the clinical development of regenerative and cell-based therapies. Similarly, the Chinese government has allowed various human embryonic stem cell research operations, encouraging researchers to investigate the clinical potential of these cells.

Key players in the market

Some of the key players profiled in the Regenerative Medicine Market include Smith & Nephew plc, Shenzhen SibionoGeneTech Co., Ltd., AstraZeneca, Aspect Biosystems, Integra LifeSciences Corporation, Novartis AG, Medtronic plc, Amgen, Inc., MiMedx Group, Baxter, Eli Lilly & Co., Mesoblast Ltd., Bayer AG, Corestem, Inc., Bluebird Bio, Inc. and Regrow Biosciences Pvt. Ltd.

Key Developments:

In January 2021, Integra LifeSciences Holdings Corporation completed the acquisition of ACell, Inc. Acquiring ACell and its proprietary MatriStem UBM technologies enabled Integra to provide more comprehensive complex wound management solutions to address patients.

In January 2021, Eli Lilly & Co. acquired Prevail Therapeutics with a deal to establish a gene therapy program at pharma giant anchored by Prevail's Adeno-Associated Virus (AAV)9-based gene therapies for patients with neurodegenerative diseases. The deal broadened their commitment to address fatal genetic forms of neurodegenerative disease through new modalities. This acquisition bought critical technology and highly skilled teams to complement the existing expertise at Lilly.

In November 2020, Novartis collaborated with Mesoblast to develop, commercialize and manufacture remestemcel-L for treatment of Acute Respiratory Distress Syndrome (ARDS). As a potential first ARDS therapy, remestemcel-L used Mesenchymal Stromal Cells (MSCs), a cell-based platform technology, to treat this deadly condition and improve outcomes. Novartis intended to initiate a Phase III study in non-COVID-19-related ARDS after the anticipated closing of this license agreement.

In October 2020, Bayer acquired Asklepios BioPharmaceutical to broaden the innovation base in cell and gene therapy. This fueled Bayer's cell and gene therapy platform with potential to bring treatments to patients across multiple disease areas with high unmet need.

In October 2018, Mesoblast Limited expanded its partnership with JCR Pharmaceuticals Co. Ltd. in Japan to the use of mesenchymal stem cells (MSCs) for the treatment of new-borns who lack sufficient blood supply and oxygen to the brain, a condition termed neonatal hypoxic ischemic encephalopathy (HIE).

Products Covered:

  • Progenitor and Stem Cell Therapies
  • Gene Therapies
  • Tissue-Engineering
  • Cell Therapies
  • Other Products

Materials Covered:

  • Genetically Engineered Material
  • Synthetic material
  • Biologically derived material
  • Pharmaceutical

Applications Covered:

  • Oncology
  • Wound Care
  • Cardiovascular
  • Musculoskeletal
  • Ophthalmology
  • Other Applications

End Users Covered:

  • Government & Academic Research Institutes
  • Hospitals & Clinics
  • Commercial Industries

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2020, 2021, 2022, 2025, and 2028
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 Application Analysis
  • 3.8 End User Analysis
  • 3.9 Emerging Markets
  • 3.10 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Regenerative Medicine Market, By Product

  • 5.1 Introduction
  • 5.2 Progenitor and Stem Cell Therapies
  • 5.3 Gene Therapies
  • 5.4 Tissue-Engineering
  • 5.5 Cell Therapies
  • 5.6 Other Products

6 Global Regenerative Medicine Market, By Material

  • 6.1 Introduction
  • 6.2 Genetically Engineered Material
    • 6.2.1 Transgenics
    • 6.2.2 Genetically Manipulated Cell
    • 6.2.3 Gene-Activated Matrices
    • 6.2.4 Neural Stem Cell
    • 6.2.5 Three-Dimensional Polymer Technology
    • 6.2.6 Fibroblast
  • 6.3 Synthetic material
    • 6.3.1 Artificial vascular graft material
    • 6.3.2 Hydrogel material
    • 6.3.3 Scaffold
  • 6.4 Biologically derived material
    • 6.4.1 Xenogeneic material
    • 6.4.2 Collagen
  • 6.5 Pharmaceutical
    • 6.5.1 Biologic

7 Global Regenerative Medicine Market, By Application

  • 7.1 Introduction
  • 7.2 Oncology
  • 7.3 Wound Care
  • 7.4 Cardiovascular
  • 7.5 Musculoskeletal
  • 7.6 Ophthalmology
  • 7.7 Other Applications

8 Global Regenerative Medicine Market, By End User

  • 8.1 Introduction
  • 8.2 Government & Academic Research Institutes
  • 8.3 Hospitals & Clinics
  • 8.4 Commercial Industries

9 Global Regenerative Medicine Market, By Geography

  • 9.1 Introduction
  • 9.2 North America
    • 9.2.1 US
    • 9.2.2 Canada
    • 9.2.3 Mexico
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 Italy
    • 9.3.4 France
    • 9.3.5 Spain
    • 9.3.6 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 Japan
    • 9.4.2 China
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 New Zealand
    • 9.4.6 South Korea
    • 9.4.7 Rest of Asia Pacific
  • 9.5 South America
    • 9.5.1 Argentina
    • 9.5.2 Brazil
    • 9.5.3 Chile
    • 9.5.4 Rest of South America
  • 9.6 Middle East & Africa
    • 9.6.1 Saudi Arabia
    • 9.6.2 UAE
    • 9.6.3 Qatar
    • 9.6.4 South Africa
    • 9.6.5 Rest of Middle East & Africa

10 Key Developments

  • 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 10.2 Acquisitions & Mergers
  • 10.3 New Product Launch
  • 10.4 Expansions
  • 10.5 Other Key Strategies

11 Company Profiling

  • 11.1 Smith & Nephew plc
  • 11.2 Shenzhen SibionoGeneTech Co., Ltd.
  • 11.3 AstraZeneca
  • 11.4 Aspect Biosystems
  • 11.5 Integra LifeSciences Corporation
  • 11.6 Novartis AG
  • 11.7 Medtronic plc
  • 11.8 Amgen, Inc.
  • 11.9 MiMedx Group
  • 11.10 Baxter
  • 11.11 Eli Lilly & Co.
  • 11.12 Mesoblast Ltd.
  • 11.13 Bayer AG
  • 11.14 Corestem, Inc.
  • 11.15 Bluebird Bio, Inc.
  • 11.16 Regrow Biosciences Pvt. Ltd.

List of Tables

  • 1 Global Regenerative Medicine Market Outlook, By Region (2020-2028) ($MN)
  • 2 Global Regenerative Medicine Market Outlook, By Product (2020-2028) ($MN)
  • 3 Global Regenerative Medicine Market Outlook, By Progenitor and Stem Cell Therapies (2020-2028) ($MN)
  • 4 Global Regenerative Medicine Market Outlook, By Gene Therapies (2020-2028) ($MN)
  • 5 Global Regenerative Medicine Market Outlook, By Tissue-Engineering (2020-2028) ($MN)
  • 6 Global Regenerative Medicine Market Outlook, By Cell Therapies (2020-2028) ($MN)
  • 7 Global Regenerative Medicine Market Outlook, By Other Products (2020-2028) ($MN)
  • 8 Global Regenerative Medicine Market Outlook, By Material (2020-2028) ($MN)
  • 9 Global Regenerative Medicine Market Outlook, By Genetically Engineered Material (2020-2028) ($MN)
  • 10 Global Regenerative Medicine Market Outlook, By Transgenics (2020-2028) ($MN)
  • 11 Global Regenerative Medicine Market Outlook, By Genetically Manipulated Cell (2020-2028) ($MN)
  • 12 Global Regenerative Medicine Market Outlook, By Gene-Activated Matrices (2020-2028) ($MN)
  • 13 Global Regenerative Medicine Market Outlook, By Neural Stem Cell (2020-2028) ($MN)
  • 14 Global Regenerative Medicine Market Outlook, By Three-Dimensional Polymer Technology (2020-2028) ($MN)
  • 15 Global Regenerative Medicine Market Outlook, By Fibroblast (2020-2028) ($MN)
  • 16 Global Regenerative Medicine Market Outlook, By Synthetic material (2020-2028) ($MN)
  • 17 Global Regenerative Medicine Market Outlook, By Artificial vascular graft material (2020-2028) ($MN)
  • 18 Global Regenerative Medicine Market Outlook, By Hydrogel material (2020-2028) ($MN)
  • 19 Global Regenerative Medicine Market Outlook, By Scaffold (2020-2028) ($MN)
  • 20 Global Regenerative Medicine Market Outlook, By Biologically derived material (2020-2028) ($MN)
  • 21 Global Regenerative Medicine Market Outlook, By Xenogeneic material (2020-2028) ($MN)
  • 22 Global Regenerative Medicine Market Outlook, By Collagen (2020-2028) ($MN)
  • 23 Global Regenerative Medicine Market Outlook, By Pharmaceutical (2020-2028) ($MN)
  • 24 Global Regenerative Medicine Market Outlook, By Biologic (2020-2028) ($MN)
  • 25 Global Regenerative Medicine Market Outlook, By Application (2020-2028) ($MN)
  • 26 Global Regenerative Medicine Market Outlook, By Oncology (2020-2028) ($MN)
  • 27 Global Regenerative Medicine Market Outlook, By Wound Care (2020-2028) ($MN)
  • 28 Global Regenerative Medicine Market Outlook, By Cardiovascular (2020-2028) ($MN)
  • 29 Global Regenerative Medicine Market Outlook, By Musculoskeletal (2020-2028) ($MN)
  • 30 Global Regenerative Medicine Market Outlook, By Ophthalmology (2020-2028) ($MN)
  • 31 Global Regenerative Medicine Market Outlook, By Other Applications (2020-2028) ($MN)
  • 32 Global Regenerative Medicine Market Outlook, By End User (2020-2028) ($MN)
  • 33 Global Regenerative Medicine Market Outlook, By Government & Academic Research Institutes (2020-2028) ($MN)
  • 34 Global Regenerative Medicine Market Outlook, By Hospitals & Clinics (2020-2028) ($MN)
  • 35 Global Regenerative Medicine Market Outlook, By Commercial Industries (2020-2028) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.